PolyPeptide Group AG (PPGN) - Financial and Strategic SWOT Analysis Review
Description
PolyPeptide Group AG (PPGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
PolyPeptide Group AG (PolyPeptide) is a contract development and manufacturing organization (CDMO) that develops and commercializes generic peptides and peptide-related molecules. The company develops generic peptides, custom research-grade peptides, radiolabeled peptides and oligonucleotides. It provides services including pre-GMP development, inspection, quality control, regulatory support, process development and optimization. The company operates a global manufacturing network with facilities in Europe, the US, and India, targeting international markets. PolyPeptide is headquartered in Baar, Zug, Switzerland.
PolyPeptide Group AG Key Recent Developments
Dec 12,2025: Lupin Manufacturing Solutions and Polypeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
Dec 12,2025: PolyPeptide and Lupin Manufacturing Solutions Form Alliance to Strengthen Peptide Supply for Metabolic Therapies
Oct 28,2025: Lifecore and PolyPeptide Collaborate on End-to-End Peptide Manufacturing Solution for U.S. Market
Oct 28,2025: Lifecore and PolyPeptide Collaborate to Provide End-to-End Peptide Manufacturing Solution for U.S. Market
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
PolyPeptide Group AG (PolyPeptide) is a contract development and manufacturing organization (CDMO) that develops and commercializes generic peptides and peptide-related molecules. The company develops generic peptides, custom research-grade peptides, radiolabeled peptides and oligonucleotides. It provides services including pre-GMP development, inspection, quality control, regulatory support, process development and optimization. The company operates a global manufacturing network with facilities in Europe, the US, and India, targeting international markets. PolyPeptide is headquartered in Baar, Zug, Switzerland.
PolyPeptide Group AG Key Recent Developments
Dec 12,2025: Lupin Manufacturing Solutions and Polypeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
Dec 12,2025: PolyPeptide and Lupin Manufacturing Solutions Form Alliance to Strengthen Peptide Supply for Metabolic Therapies
Oct 28,2025: Lifecore and PolyPeptide Collaborate on End-to-End Peptide Manufacturing Solution for U.S. Market
Oct 28,2025: Lifecore and PolyPeptide Collaborate to Provide End-to-End Peptide Manufacturing Solution for U.S. Market
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
48 Pages
- Section 1 - About the Company
- PolyPeptide Group AG - Key Facts
- PolyPeptide Group AG - Key Employees
- PolyPeptide Group AG - Key Employee Biographies
- PolyPeptide Group AG - Major Products and Services
- PolyPeptide Group AG - History
- PolyPeptide Group AG - Company Statement
- PolyPeptide Group AG - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- PolyPeptide Group AG - Business Description
- Other Break-up: Asia Pacific
- Performance
- Other Break-up: Contract Manufacturing
- Overview
- Performance
- Other Break-up: Custom Projects
- Overview
- Performance
- Other Break-up: Generics and Cosmetics
- Overview
- Performance
- Geographical Segment: Americas
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: Others
- Performance
- R&D Overview
- PolyPeptide Group AG - Corporate Strategy
- PolyPeptide Group AG - SWOT Analysis
- SWOT Analysis - Overview
- PolyPeptide Group AG - Strengths
- PolyPeptide Group AG - Weaknesses
- PolyPeptide Group AG - Opportunities
- PolyPeptide Group AG - Threats
- PolyPeptide Group AG - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- PolyPeptide Group AG, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Dec 12, 2025: PolyPeptide and Lupin Manufacturing Solutions Form Alliance to Strengthen Peptide Supply for Metabolic Therapies
- Dec 12, 2025: Lupin Manufacturing Solutions and Polypeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
- Oct 28, 2025: Lifecore and PolyPeptide Collaborate on End-to-End Peptide Manufacturing Solution for U.S. Market
- Oct 28, 2025: Lifecore and PolyPeptide Collaborate to Provide End-to-End Peptide Manufacturing Solution for U.S. Market
- Oct 24, 2025: Capacity Expansion Underway at Our Ambernath Facility
- Sep 29, 2025: Capacity Expansion for Major Pharma’s Hormonal Disorders and Women’s Health Portfolio
- Sep 22, 2025: PolyPeptide Group Reaches Key Milestone in Malmö Expansion
- Aug 12, 2025: PolyPeptide Announces Results for H1 2025
- Mar 11, 2025: Polypeptide with Substantial Improvements in Profitability and Cash Flow, Positioned for Strong Growth
- Jan 13, 2025: Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- PolyPeptide Group AG, Key Facts
- PolyPeptide Group AG, Key Employees
- PolyPeptide Group AG, Key Employee Biographies
- PolyPeptide Group AG, Major Products and Services
- PolyPeptide Group AG, History
- PolyPeptide Group AG, Subsidiaries
- PolyPeptide Group AG, Key Competitors
- PolyPeptide Group AG, Ratios based on current share price
- PolyPeptide Group AG, Annual Ratios
- PolyPeptide Group AG, Annual Ratios (Cont...1)
- PolyPeptide Group AG, Annual Ratios (Cont...2)
- PolyPeptide Group AG, Interim Ratios
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- PolyPeptide Group AG, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- PolyPeptide Group AG, Performance Chart (2020 - 2024)
- PolyPeptide Group AG, Ratio Charts
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- PolyPeptide Group AG, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

